|
|
|
| Clinical Efficacy of Different Doses of Sakubactrovalsartan in Patients with Hypertension Complicated with Chronic Heart Failure |
| DONG Wang-li, LEI Jie-yu, SHI Wen-tao |
| Shaanxi Kangfu Hospital, Xi'an Shaanxi 710065 |
|
|
|
|
Abstract 【Objective】 To investigate the clinical efficacy of different doses of Sakubatroxvalsartan in the treatment of hypertensive patients with CHF. 【Methods】 From January 2019 to January 2022, 100 patients with hypertension and CHF admitted to the Affiliated Hospital of Yan'an University were randomly divided into a large dose group (conventional treatment + Sakubatroxvalsartan tablets 100 mg) and a small dose group (conventional treatment + Sakubatroxvalsartan tablets 50 mg) according to the random number table. Two groups were compared in terms of efficacy, serum levels of high sensitivity C-reactive protein (hs-CRP), endothelin-1 (ET-1), N-terminal-proBNP, cardiac function indicators, and adverse reactions after treatment. 【Results】The total effective rate of the high-dose group was 90.00% (45/50), significantly higher than the 72.00% (36/50) of the low-dose group, with a statistically significant difference (P<0.05). After treatment, the serum levels of hs-CRP and ET-1 in both groups were lower than those before treatment, and the high-dose group was lower than the low-dose group, with a statistically significant difference (P<0.05); LVEDD and NT-proBNP in both groups were lower than those before treatment, while LVEF was higher than treatment; The indicators of the high-dose group were better than those of the low-dose group, and the difference was statistically significant (P<0.05). The incidence of adverse reactions was 20.00% (10/50) in the high-dose group and 10.00% (5/50) in the low-dose group, with no statistically significant difference (P>0.05). 【Conclusion】High dose Sakubatroxvalsartan is effective in the treatment of hypertension with CHF. It can reduce the level of inflammatory factors, improve the heart function of patients, and has good safety.
|
|
Received: 28 June 2022
|
|
|
|
|
|
[1] 闵宁斌,张飞龙,党玉茹,等.血清cys C、GGT与高血压患者早期器官损害风险的相关性[J].医学临床研究,2022,39(7):1098-1101.
[2] 黄鑫涛, 白保强, 李之恒, 等. 不同剂量瑞舒伐他汀对老年高血压并射血分数保留型慢性心力衰竭患者心室重构的影响[J].重庆医科大学学报, 2022, 47(1):68-73.
[3] 王宏娟, 陶启乐. 沙库巴曲缬沙坦联合美托洛尔对老年慢性心力衰竭患者心功能、血管内皮功能及神经内分泌因子的影响[J].中国老年学杂志, 2021, 41(23):5183-5187.
[4] 孙洁, 陈欣, 陈巧,等. 沙库巴曲缬沙坦对不同病因的慢性心力衰竭患者疗效比较[J].中国医院药学杂志, 2022, 42(4):422-425.
[5] 《中国高血压防治指南》修订委员会. 中国高血压防治指南2018年修订版[J].心脑血管病防治, 2019, 19(1):1-44.
[6] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志, 2018, 46(10):760-789.
[7] PIERPAOLO P, ZHANG J, JOE C, et al. High sensitivity C-reactive protein in chronic heart failure:patient characteristics, phenotypes and mode of death[J].Cardiovasc Res,2020,116(1):91-100.
[8] OFONAKARA U, OLAYEMI S, ALE K. Prevalence of hypertension and potential drug-drug interactions among chronic heart failure patients managed at lagos university teaching hospital, nigeria[J].Chest,2019, 156(4):39.
[9] 谢诚, 叶静, 缪丽燕. 61例心力衰竭患者血管紧张素受体脑啡肽酶抑制剂沙库巴曲缬沙坦的应用分析[J].中国药房, 2019, 30(8):1124-1127.
[10] 李娜, 古丽孜热木·阿布都马那甫. 比较沙库巴曲缬沙坦和缬沙坦对高血压合并慢性心力衰竭患者血管内皮功能的影响[J].河北医学,2021,27(7):1223-1227.
[11] 张跃, 李宁, 邱健,等.血管紧张素受体脑啡肽酶抑制剂沙库巴曲缬沙坦治疗高血压的研究进展[J].中华高血压杂志, 2021, 29(6):519-524.
[12] QIN L, LIU X, LI Y. Correlation of serum BNP and ET-1 levels with cardiac pump function and ventricular remodeling in patients with heart failure[J].Cell Mol Biol (Noisy-le-grand),2020, 66(3):125-131.
[13] 刘家超, 张巧玲, 陈虹,等. AMI患者血清hs-CRP、MMP9、soL-CXCL16、NT-proBNP的变化及其意义[J].四川医学, 2019, 40(6):593-596.
[14] 陈存芳, 贾博, 江珊,等. 沙库巴曲缬沙坦治疗射血分数中间值心力衰竭患者的疗效及预后[J].中国新药与临床杂志, 2020, 39(2):88-92.
[15] 中国医师协会全科医师分会. 沙库巴曲缬沙坦钠在基层心血管疾病临床应用的专家共识[J].中国全科医学, 2021, 24(23):2885-2890. |
|
|
|
2023, Vol. 40 
